scholarly journals Cases of alloimmunization with rh-antigen D in patients with uncomplicated transfusion history

2012 ◽  
Vol 93 (2) ◽  
pp. 347-348
Author(s):  
R S Gadilshina ◽  
E E Bel’skaya

Aim. To attract the attention of practicing physicians to the problem of transfusion safety of erythrocyte-containing preparations to patients at risk for the emergence of post-transfusion complications. Methods. Gel technique, diagnostic panel of erythrocytes for screening and identification of alloimmune antibodies. Results. During the study of blood samples of patients identified were alloantibodies to the D antigen of the Rh-system and provided were recommendations for blood transfusions with individual selection. Conclusion. Antibodies to erythrocyte antigens of the Rh-system can be synthesized as a result of immunization due to an incompatible blood transfusion or incompatible pregnancies, as well as in cases of intravenous drug use, in the antigen D immunized donors.

2019 ◽  
Vol 64 (2) ◽  
pp. 222-233
Author(s):  
I. A. Pashkova

Introduction. Screening and identification of anti-erythrocyte alloimmune antibodies in recipients is an important and necessary step in their testing before blood transfusion.Aim. To formulate algorithms that could facilitate the process of pre-transfusion immunohematological testing.General findings. Such a testing allows the development of post-transfusion reactions and complications to be avoided. The presence of alloantibodies of various specificities and autoantibodies in the test blood may complicate pre-transfusion testing and require the use of additional methods (adsorption, elution, etc.). The author has proposed an effective system of algorithms for conducting immunohematological studies, which can be used to identify patients at risk of developing immune post-transfusion complications and ensure an individual selection of compatible donor blood-transfusion products.


2021 ◽  
Vol 8 (4) ◽  
Author(s):  
Rollins MR ◽  
◽  
Boudreaux J ◽  
Eckman J ◽  
Branscomb J ◽  
...  

Background: Individuals with Non-Transfusion Dependent Thalassemia (NTDT) may require infrequent transfusions. Knowing transfusion history, while important, can be challenging in this subgroup. Study Design: Hospital discharge data in Georgia (2007-2016) was reviewed. Thalassemia patients were defined as ≥3 encounters with a thalassemia diagnosis code. Transfusion was defined by the presence of a diagnosis, CPT, revenue, or HCPCS code for red cell transfusion. Results: There were 428 patients identified; 57 received multi-site transfusions. Conclusion: Georgia hospitals provide intermittent transfusions to low volumes of probable NTDT patients. Patient and provider education may help assure adherence to best practices, avoiding serious transfusion complications.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4406-4406
Author(s):  
Joyce Overfield, and Pei ◽  
Lun Karen Lim

Abstract Abstract 4406 Methods of quantification of foetal red cell in maternal blood samples are important to ensure the correct administration of prophylactic anti-D to prevent sensitisation of the mother which may result in haemolytic disease of the newborn and foetus in subsequent pregnancies. We aimed to assess the accuracy of 3 methods: a gel card technique using anti-D and 2 acid-elution techniques, foetal cell detection kit (FCD, Inverclyde Biologicals Lanarkshire, Scotland) and a kit from Clin-Tech Limited (Guildford, England) based on the Kleihauer-Betke foetal stain technique (KBT), to quantifiy foetal red cells in maternal samples. The sensitivity of the gel method was also assessed. A total of 63 maternal blood samples and 30 man-made control blood samples were analysed, with only 57 maternal samples confirmed to be Rh D negative. Rh D positive samples were excluded. All samples were run concurrently with the 3 methods, according to manufacturers’ instructions. Mann Whitney test was used to compare the results. The gel technique was recorded in terms of grading of agglutination while the acid-elution kits were recorded by degree of FMH (mL). Column agglutination was also used to assess sensitivity. Results showed only 3 maternal samples were positive for FMH using the acid-elution method but not the gel technique. Statistically there was no significant difference between the techniques (Mann-Whitney test). Sensitivity of the gel method showed that it has the ability to detected FMH of more than 3mL whilst the 2 kits were able to detect FMH of 1mL. The study showed that gel technique required little skill to perform but it was not considered suitable for accurate quantification of FMH and consequently for the correct administration of prophylactic anti-D. The foetal cell detection kit (Inverclyde Biologicals) showed a similar ability to detect and quantify FMH when compared to the Kleihauer –Betke kit (Clin-Tech) with better overall staining intensity. The Kleihauer-Betke test from Clin-Tech and the foetal cell detection kit from Inverclyde Biologicals showed no significant difference (p = 0.98), thus there is no statistical significant difference between the 2 methods. However, the sensitivity of the column agglutination method was lower, as significant agglutination could only be observed with FMH of more than 3mL. The expected values were plotted based on Gomez-Arbones et al (2002), who cited significant agglutination seen when FMH is 0.1% or about 2.5mL. Sensitivity was found to be less than expected as a higher amount of bleed is required to observed significant agglutination. The FMH sample representing 1–6mL was repeated and similar findings were recorded, as significant agglutination was only observed when FMH was 4mL. The column agglutination method is not suitable as a quantitative measurement of FMH as it only allows qualitative analysis, thus if it is incorporated into a clinical setting, it must be accompanied by a quantitative test. The foetal cell detection kit has similar staining capabilities to detect foetal cells and compared to Clin-Tech was easier to use as there is no need to prepare eluting solution unlike the latter. However, fixing solution was not provided and hence need to be prepared. Results showed that only 3 maternal samples were positive for the presence of FMH and thus using a semi-quatitative acid-elution technique should be sufficient in FMH quantification unless FMH using the acid-elution technique exceeds 2mL, as recommende,d by the BCSH guidelines (2009), then the sample should be analysed using flow cytometry. Acknowledgments: Central Manchester Hospitals Transfusion Laboratory for the provision of blood samples. Performed as part of MSc Biomedical Science project, funded by Mancheste Metropolitan University. Disclosures: No relevant conflicts of interest to declare.


2017 ◽  
Vol 6 (2) ◽  
pp. 1509
Author(s):  
H. S. Lamba ◽  
Kulbir Kaur ◽  
Kulwant Kaur ◽  
Amarjit Singh Vij

<p><strong>Background:</strong> Rh D is the most important Blood Group antigen after ABO Blood group antigen for transfusion purpose. All negative blood units by routine methods must be tested to detect weak D using IAT method. When the test for D and D<sup>u</sup> is positive, the label should read Rh(D) Positive . When the test for D and D<sup>u</sup> is negative, the label should read Rh(D) Negative.</p><p><strong>Objective:</strong> To know the prevalence of weak D in the donor population. No study has been done in this part of the country earlier. It will help in the knowledge of weak D, which is very important for better patient care and prevent allo-immunzation in blood recipients.</p><p><strong>Materials and Methods:</strong> Blood samples were tested by ID Gel technique or by tube method with two anti D reagents - anti-D IgM monoclonal and blend of anti-D IgM&amp;amp;IgG. All negative samples were further tested for weak D in IAT phase by LISS/Coombs' gel card.</p><p><strong>Results:</strong> A total of 13043 samples were tested from January 2011 to December 2013. 12196 were Rh positive and 847 were Rh D negative. Weak D was positive in 8 samples.</p><p><strong>Conclusion:</strong> The study shows the prevalence of weak D as 0.07% in blood donors who were primarily from in and around Jalandhar in Punjab. These donors may have posed problem to the recipients of blood and blood product and their detection prevented them from alloimunisation.</p>


Author(s):  
Anila Mani, ◽  
Poornima AP ◽  
Debasish Gupta

Background: The blocking of D antigen sites of RBC membrane of the fetus by the passively transferred IgG anti-D in cases of Hemolytic Disease of fetus and new born (HDFN) is called blocked- D phenomenon. The coating of maternal IgG type of anti-D prevents the agglutination of the Rh-(D) antigen positive red blood cells (RBC) by the IgM D-antigen typing reagents. We are reporting two cases of Rh-(D) HDFN which were falsely typed as Rh (D) antigen negative with routine typing reagents and had multiple allo-antibodies in the maternal serum. Aims: To rule out HDFN and to confirm the Rh-(D) status of baby, to detect the presence of other allo-antibodies in the maternal serum that can complicate future transfusions in mother. Materials: After routine blood grouping, sample of baby was subjected to adsorption-elution studies and maternal serum was used for antibody screening and identification Results: In both the cases, blocked-D phenomenon got detected and there were multiple anti-rhesus antibodies other than anti-D in the maternal serum. Conclusion: Antibody identification in antenatal women is important in the case management of HDFN to protect future pregnancies and to avoid the risk of mismatched transfusions.


2020 ◽  
Author(s):  
Marthe Jørgensen ◽  
Jan Cato Holter ◽  
Erik Egeland Christensen ◽  
Camilla Schjalm ◽  
Kristian Tonby ◽  
...  

Abstract Background: In SARS-CoV-2 infection there is an urgent need to identify patients that will progress to severe COVID-19 and may benefit from targeted treatment.Objectives: Analyze plasma cytokines in COVID-19 patients and investigate their association with respiratory failure (RF) and treatment in Intensive Care Unit (ICU). Method: Hospitalized patients (n=34) with confirmed COVID-19 were recruited into a prospective cohort study. Clinical data and blood samples were collected at inclusion and after 2-5 and 7-10 days. RF was defined as PaO2/FiO2 ratio (P/F) <40kPa. Plasma cytokines were analyzed by a Human Cytokine 27-plex assay. Measurements and Results: COVID-19 patients with RF and/or treated in ICU showed overall increased systemic cytokine levels. Plasma IL-6, IL-8, G-CSF, MCP-1, MIP-1α levels were negatively correlated with P/F, whereas combinations of IL-6, IP-10, IL-1ra and MCP-1 showed the best association with RF in ROC analysis (AUC 0.79-0.80, p<0.05). During hospitalization the decline was most significant for IP-10 (P<0.001). Conclusion: Elevated levels of pro-inflammatory cytokines were present in patients with severe COVID-19. IL-6 and MCP-1 were inversely correlated with P/F with the largest AUC in ROC analyses and should be further explored as biomarkers to identify patients at risk for severe RF and as targets for improved treatment strategies.


2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S325-S326
Author(s):  
X Zhu ◽  
K Chao ◽  
X Gao ◽  
M Huang ◽  
X D Wang

Abstract Background Thiopurine drugs plays an important role for immunosuppressive therapy in inflammatory bowel disease. The molecular mechanism of the thiopurine toxicity is primarily mediated by DNA-incorporated thioguanine nucleotides (DNA-TGN). The aim of this study was to assess the impact of DNA-TGN levels on thiopurine-induced toxicity. Methods Patients over 18 years who were diagnosed with IBD and prescribed on thiopurines from February 2019 to August 2019 were recruited. All of them were genotyped with NUDT15 R139C before the thiopurine therapy. A novel assay was established to measure levels of DNA-TGN in blood leucocytes. The DNA-TGN and 6TGN levels were correlated with clinical toxicity. Results 185 patients with Crohn’s disease and 5 patients with ulcerative colitis were included in this study. DNA-TGN and 6TGN levels could be quantified in 229 patients’ blood samples. Thiopurine-induced leukopoenia (TIL) arose in 19 individuals with the median 6TGN level of 308.0 pmol/8×108 RBC which was not significantly different from the patients without TIL (p = 0.050). However, there was a significant association between DNA-TGN levels and TIL. Patients who developed TIL were identified with a higher DNA-TGN levels compared with those who did not (p = 0.00030, 456.9 (63.3–879.2) vs. 268.9 (45.6–916.8) fmol/μg DNA). The area under the ROC curves of the continuous DNA-TGN concentration to predict TIL was 0.75 (95% CI: 0.63~0.87) and almost 84% (16/19) of the TIL could be explained based on the DNA-TGN cut-off value of 343.9 fmol/μg DNA Conclusion This study shows that quantification of DNA-TGN levels can be applied to gauge thioprine therapy and avoid TIL after pre-genotyping NUDT15 R139C in inflammatory bowel disease patients.


2020 ◽  
Vol 14 (9) ◽  
Author(s):  
Miran Kenk ◽  
Jean Grégoire ◽  
Marc-Andre Coté ◽  
Kim A. Connelly ◽  
Margot K. Davis ◽  
...  

In clinical practice, cancer management does not consistently encompass screening and identification of cardiovascular (CV) risk. The use of androgen deprivation therapy (ADT) in prostate cancer has been associated with increased CV risk and development of metabolic syndrome, necessitating identification of patients at risk in this population (e.g., those with pre-existing CV disease). A multi-disciplinary team of Canadian physicians was assembled to develop a series of recommendations intended to identify patients who may benefit from optimal management of their cardiovascular disease and/or modification of cardiac risk factors. A key goal was the development of a simple screening tool for identification of patients with pre-existing CV disease. This simple and inclusive set of recommendations are intended for use within urology clinics to facilitate holistic approaches and simplify the management of patients.


2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Adham Abu Taha ◽  
Ahmad Yaseen ◽  
Sa’d Suleiman ◽  
Omar Abu Zenah ◽  
Hammam Ali ◽  
...  

Background. β-Thalassemia is a common inherited hemolytic disorder in Palestine. Red blood cell (RBC) transfusion is the principal treatment but it may cause RBC alloimmunization. This study was conducted to determine the prevalence and characteristics of RBC alloimmunization among thalassemic patients in northern governorates of Palestine. Methods. A prospective multicenter observational study was conducted in the thalassemia transfusion centers in the northern governorates of Palestine. The study included 215 thalassemia patients who received regular blood transfusions. Clinical and transfusion records of patients were examined. Antibody screening and identification was conducted using the microcolum gel technique. Results. Two hundred fifteen patients were included in the study. More than half (52.1%) of the patients were males. The median age of patients was 18 years (range: 12–24 years). The most frequent blood group was A (40.5%). Alloantibodies were detected in 12.6% of patients. Anti-D (33.3%), anti-K (25.9%) and anti-E (14.8%) were the most commonly isolated antibodies. There was no association between age, sex, starting age of transfusion, number of transfused units, history of splenectomy and alloimmunization. Conclusions. Anti-Rh and anti-K antibodies were common among this cohort of patients. Age, sex, starting age of transfusion, number of transfused units, and history of splenectomy could not predict the occurrence of alloimmunization.


2009 ◽  
Vol 58 (8) ◽  
pp. 1106-1111 ◽  
Author(s):  
Nele Wellinghausen ◽  
Dunja Siegel ◽  
Juliane Winter ◽  
Susanne Gebert

This study prospectively evaluated an 18S rRNA gene-targeted real-time PCR approach in comparison with standard blood culture (BC) diagnostics for rapid diagnosis of candidaemia in a large study population of 384 patients, including 902 whole blood samples from 468 infectious episodes (IEs) of 329 adults and 55 children with haematological malignancies and various forms of immunodeficiency, and intensive care unit patients. Seven out of eight BC-proven cases (87.5 %) of candidaemia and seven out of twelve BC-positive samples (58.3 %) were positive by the Candida-specific PCR. A positive PCR result was also obtained for 28/460 BC-negative samples from IEs, including 8 patients with culture-confirmed Candida infection at primary sterile body sites. Of the PCR-positive, culture-negative patients, more than 50 % received systemic antifungal therapy. In 432/460 BC-negative IEs, the Candida specific-PCR was negative, resulting in a negative predictive value of 99.8 %. In conclusion, the Candida specific-PCR approach facilitates rapid detection of Candida DNA in blood samples of patients at risk of candidaemia within a few hours. Although standard BC diagnostics appear to remain indispensable for the detection of all cases of candidaemia, this PCR assay allowed the detection of candidaemia at a mean of 3 days earlier than BC diagnostics. Thus, it enables earlier antifungal therapy for patients with suspected candidaemia and may prevent further complications.


Sign in / Sign up

Export Citation Format

Share Document